These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 17050869

  • 1. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
    Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, Prager D, Monberg MJ, Ye Z, Obasaju CK.
    J Clin Oncol; 2006 Oct 20; 24(30):4840-7. PubMed ID: 17050869
    [Abstract] [Full Text] [Related]

  • 2. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N.
    J Clin Oncol; 2009 Oct 01; 27(28):4787-92. PubMed ID: 19720897
    [Abstract] [Full Text] [Related]

  • 3. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
    Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, O'Brien M, Peterson PM, Castellano D, Selvaggi G, Novello S, Blatter J, Kayitalire L, Crino L, Paz-Ares L.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):690-6. PubMed ID: 15701857
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.
    Garin A, Manikhas A, Biakhov M, Chezhin M, Ivanchenko T, Krejcy K, Karaseva V, Tjulandin S.
    Breast Cancer Res Treat; 2008 Jul 15; 110(2):309-15. PubMed ID: 17851759
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A.
    J Clin Oncol; 2006 Mar 20; 24(9):1443-8. PubMed ID: 16549838
    [Abstract] [Full Text] [Related]

  • 8. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M.
    Clin Lung Cancer; 2013 May 20; 14(3):215-23. PubMed ID: 23332288
    [Abstract] [Full Text] [Related]

  • 9. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M.
    Clin Cancer Res; 2009 Jan 01; 15(1):382-9. PubMed ID: 19118069
    [Abstract] [Full Text] [Related]

  • 10. Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.
    Ferraldeschi R, Thatcher N, Lorigan P.
    Expert Rev Anticancer Ther; 2007 May 01; 7(5):635-40. PubMed ID: 17492928
    [Abstract] [Full Text] [Related]

  • 11. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE.
    Clin Cancer Res; 2007 Jan 15; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [Abstract] [Full Text] [Related]

  • 12. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR, Hatfield AK, Hillman S, Bauman MD, Mailliard JA, Kugler JW, Morton RF, Marks RS, Levitt R.
    Cancer; 2003 May 15; 97(10):2498-503. PubMed ID: 12733149
    [Abstract] [Full Text] [Related]

  • 13. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
    Clarke SJ, Boyer MJ, Millward M, Underhill C, Moylan E, Yip D, White S, Childs A, Beale P, Latz J, Suri A, Iglesias JL.
    Lung Cancer; 2005 Sep 15; 49(3):401-12. PubMed ID: 15923057
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
    Specenier PM, Ciuleanu T, Latz JE, Musib LC, Darstein CL, Vermorken JB.
    Cancer Chemother Pharmacol; 2009 Jul 15; 64(2):233-41. PubMed ID: 19011858
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT.
    J Clin Oncol; 2008 Dec 10; 26(35):5761-6. PubMed ID: 19001330
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M.
    Cancer Chemother Pharmacol; 2012 Aug 10; 70(2):271-6. PubMed ID: 22752216
    [Abstract] [Full Text] [Related]

  • 17. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
    Kakolyris S, Agelidou A, Androulakis N, Tsaroucha E, Kouroussis Ch, Agelidou M, Karvounis N, Veslemes M, Christophylakis Ch, Argyraki A, Geroyianni A, Georgoulias V.
    Lung Cancer; 2006 Jul 10; 53(1):59-65. PubMed ID: 16716447
    [Abstract] [Full Text] [Related]

  • 18. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH, McCune JS, Lindley C, Faucette S, Shord S, Donahue A, Socinski MA, Stewart CF, Zamboni WC, Kirstein MN, Moore D.
    Cancer Invest; 2005 Jul 10; 23(6):511-9. PubMed ID: 16203659
    [Abstract] [Full Text] [Related]

  • 19. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, Ulm K, Hessler S, Gatzemeier U.
    Lung Cancer; 2006 Jul 10; 53(1):67-75. PubMed ID: 16713013
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD.
    J Clin Oncol; 2009 Jul 10; 27(20):3284-9. PubMed ID: 19433684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.